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ABSTRACT
Background: Stress ulcer prophylaxis is an integral part of the care of the critically 
ill. Agents that alter gastric pH may predispose these patients to gastric colonisation, 
with subsequent pneumonia and/or sepsis. Cytoprotective agents such as sucralfate 
preserve gastric acidity and may be protective.  
Objective: To determine whether African patients on sucralfate as stress-ulcer 
prophylaxis have a lower incidence of gastric colonisation and ventilator-associated 
pneumonia than those on ranitidine.
Design: Randomised case-control study 
Setting: Kenyatta National Hospital Intensive Care Unit 
Subjects: Patients on ventilatory support for 48 hours or more
Interventions: Sixty-eight critically ill patients were randomly assigned to either 
ranitidine or sucralfate as stress ulcer prophylaxis. Paired samples were taken from 
gastric and tracheal aspirates at admission, 48 hours and day six. Pneumonia was 
diagnosed using the Clinical Pulmonary Infection Score. 
Main outcome measures: Death or the development of pneumonia. 
Results: Although gastric colonisation rates were similar in the two groups, the incidence 
of pneumonia was lower in the sucralfate group (17.6% vs. 23.5%, p=0.4). In 63.6% 
of patients with both gastric colonisation and airway infection, the same organism 
was isolated from the two sites (p<0.01). The majority of the organisms isolated were 
multi-drug resistant.
Conclusion: Compared with ranitidine, sucralfate did not offer significant reduction in 
either gastric colonisation or ventilator-associated pneumonia in critically ill African 
patients.
INTRODUCTION
Pneumonia is the leading cause of death from hospital-
acquired infections (1). Infections are classified as 
nosocomial if there is no evidence that they were 
present or incubating at the time of admission to 
hospital. They generally occur after 48 to 72 hours of 
admission or within ten days of discharge. Ventilator-
associated pneumonia is nosocomial pneumonia in 
patients who have been on mechanical ventilation for 
48 hours or more, and is the second most common 
hospital-acquired infection (1-3). 
 Nosocomial pneumonia affects more than 
250,000 acute care patients every year in the United 
States, accounting for up to 18% of all nosocomial 
infections (1,4). The incidence is 20 times greater in 
critically ill patients and 21 times more common in the 
intubated patient (5). A study based in the Kenyatta 
National Hospital ICU in 1993 found a 35.7% incidence 
of pneumonia among intubated patients (8). Although 
ICUs make up only 5% of hospital beds and care for 
less than 10% of hospital patients, infections in these 
units account for more than 20% of hospital-acquired 
infections (5).
 VAP that occurs within 48 to 72 hours of tracheal 
intubation is termed early-onset pneumonia. It often 
results from aspiration at the time of intubation. 
The organisms responsible are often antibiotic-
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sensitive bacteria such as Haemophilus influenza, 
Streptococcus pneumoniae and coagulase-negative 
Staphylococcus aureus. VAP that occurs after 72 hours 
is called late-onset pneumonia, commonly due to 
antibiotic-resistant organisms including Pseudomonas 
aeruginosa, Methicillin-Resistant Staphylococcus aureus 
(MRSA), Acinetobacter and Enterobacter species. The 
European Prevalence of Infection in Intensive Care 
(EPIC) study found that VAP was responsible for an 
estimated 45% of all infections in ICUs across Europe 
(6). The German National Infection Surveillance 
System (KISS) of 2012 established that a significant 
number of nosocomial infections in European ICUs 
were attributable to multi-drug resistant gram-
negative organisms (4,7). 
 Nosocomial pneumonia prolongs the critically 
ill patient’s stay in ICU, lengthens the duration of 
mechanical ventilation and ultimately increases the 
cost of care (4). Mortality rates are notably high in 
patients with nosocomial pneumonia, ranging from 
20-60%, depending on the severity of the underlying 
disease (9,10). 
 The mortality in mechanically ventilated patients 
treated with pH-altering agents has been found to be 
up to 1.6 times greater than predicted mortality, based 
on ICU mortality scoring systems such as APACHE 
II (9). This has been attributed to the development of 
higher rates of VAP and septicaemia in these patients. 
The use of cytoprotective agents such as sucralfate, 
rather than pH-altering agents such as ranitidine, 
has been shown to lower the incidence of nosocomial 
pneumonia from 20% to as low as 5% in one study 
(11) and from 36% to 10% in a different study (12). It 
has also been shown to reduce gastric colonisation 
from 48% to 28%. In addition, sucralfate is a much 
cheaper alternative than ranitidine, an important 
consideration for a resource-limited country. 
 In health, equilibrium exists between pathogens, 
the environment and natural host defence 
mechanisms. For infection to occur, this equilibrium 
will have been disrupted. Critical illness leads to an 
acquired immunodeficiency state, largely due to 
the severity of the underlying disease or injury. The 
organisms most frequently isolated in critically ill 
patients with airway colonisation and/or infection 
are gram-negative, with a total frequency of 62.5%. 
Often, these are organisms from the patient’s own 
gastric contents. The presence of a nasogastric tube, 
as is commonly found in intubated patients, impairs 
the function of the gastro-oesophageal sphincter. 
Passive gastro-oesophageal reflux of infected 
contents therefore occurs, with micro-aspiration and 
subsequent pneumonia. Gastric colonisation and 
VAP rates have not been established in critically ill 
African patients. 
 Enhanced bacterial pathogenicity in critical 
care units, coupled with the numerous invasive 
diagnostic and therapeutic procedures performed 
there that bypass local host defence mechanisms, also 
predispose these patients to nosocomial infections. 
Endotracheal tubes prevent the clearing of the 
airway by the mucocilliary apparatus, facilitating 
bacterial colonisation of the tracheobronchial tree. 
Further, pooling of contaminated secretions above 
the endotracheal tube cuff leads to aspiration of 
contaminated secretions. Other variables that 
are independently associated with nosocomial 
pneumonia include age greater than 70 years, 
underlying disease, shock, depressed consciousness, 
re-intubation, smoking, obesity and malnutrition. 
Artificial ventilation alone as an exogenous risk factor 
for nosocomial infection contributes 27.6% to that 
risk.
 There is no standard test for the diagnosis of 
VAP and no standard method to exclude pulmonary 
infections in mechanically ventilated patients with 
fever and multi-organ dysfunction. The Clinical 
Pulmonary Infection Score (CPIS) is commonly 
employed, although this scoring system has been 
criticised as being of low specificity. Bronchoscopically 
directed techniques have specificity rates of 78-
89% and positive predictive values of 83-91%. 
Cost however is still the greatest limiting factor to 
the widespread use of bronchoscopy to diagnose 
pneumonia in ICUs in the developing world.
Main Objective
To compare the incidence of ventilator-associated 
pneumonia (VAP) in mechanically ventilated critically 
ill African patients on ranitidine as stress ulcer 
prophylaxis versus sucralfate.
Specific Objectives
1. To compare the incidence of VAP in patients on 
sucralfate and those on ranitidine on the basis of 
the CPIS scoring system.
2. To compare the degree of gastric colonisation in 
the two groups of patients.
3. To determine whether there is any association 
between the organisms present in gastric aspirates 
and those causing pneumonia in the two groups 
of patients.
Justification of the Study
Stress ulcer prophylaxis with pH-altering agents such 
as ranitidine is routinely carried out on ventilated 
patients in the Kenyatta National Hospital ICU. 
Sucralfate however, is a much cheaper alternative. 
The fact that sucralfate may also serve to reduce 
the incidence of VAP would have far-reaching 
implications as it would lead to a reduction in 
ventilator days and a reduction in the need for 
expensive antibiotics, reducing morbidity as well as 
lowering the cost of care. 
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MATERIALS AND METHODS
This was a prospective, randomised case-control 
study, based at the Kenyatta National Hospital ICU. 
Critically ill patients who had been on ventilatory 
support for a minimum of 48 hours were eligible for 
inclusion into the study. Exclusion criteria included 
patients with any respiratory tract infection at 
admission, positive bacterial cultures from baseline 
tracheal aspirates, patients on treatment for peptic 
ulcer disease, documented upper gastrointestinal 
bleeding, previous gastrectomy, patients without 
nasogastric tubes, patients transferred from other 
ICUs and patients who had been on antibiotics prior 
to admission.
Statistical methods: We estimated that 31 patients per 
group would provide an 80% power for a two-sided 
test to detect a 20% reduction in gastric colonisation 
rates between the two groups, at the 0.05 level. 
Results were analysed using the Statistical Package for 
Social Sciences (SPSS) software. Categorical variables 
were expressed as numbers and frequencies and 
compared using Chi-squared tests for significance. 
Logistic regression was used to test for confounders. 
Probability levels of <0.05 were considered statistically 
significant.
Recruitment: This study was approved by the 
Kenyatta National Hospital Ethical and Research 
Committee. Written informed consent was obtained 
from guardians or next-of-kin. Consecutive patients 
admitted to the Kenyatta National Hospital ICU for 
mechanical ventilation were randomly assigned to 
receive either intravenous ranitidine 50mg eight-
hourly or sucralfate 1gram via nasogastric tube six-
hourly (for patients below 12 years of age, ranitidine 
0.5mg/kg eight-hourly or sucralfate 10-20mg/kg six 
hourly was given). Only patients still on mechanical 
ventilation 48 hours later were included in the study, 
remaining in the assigned treatment group. 
 Each patient had a thorough history and physical 
examination on admission. They then had tracheal 
aspirate cultures, gastric aspirate cultures, full blood 
counts and chest X-rays on admission, at 48 hours 
and on day six. All tracheal and gastric samples were 
taken to the KEMRI Nairobi lab for microbiological 
analysis. VAP was diagnosed using the CPIS score 
which includes new and persistent infiltrates on 
chest X-ray, temperature greater that 38.5°C or less 
than 36°C, white cell counts above 2,000/ul or below 
4,000/ul, purulent tracheobronchial secretions, a 
PaO2/FIO2 ratio less than 250 and the absence of 
alternative sources of infection. Mortality prediction 
was performed within 24 hours of admission using 
the APACHE II scoring system.
RESULTS
There were 447 admissions during the study period. 
80 patients admitted to the Kenyatta National Hospital 
ICU who met the inclusion criteria were recruited 
into the study, and randomly assigned to receive 
either ranitidine or sucralfate. Twelve patients were 
subsequently excluded for the following reasons: Five 
died before 48 hours, three were extubated before 48 
hours and four had positive bacterial cultures in the 
baseline tracheal aspirate. The remaining 68 were 




Ranitidine (n=34) Sucralfate (n=34) p-value
Sex – no (%) NS
Male 18 (52.9%) 19 (55.9%) NS
Female 16 (47.1) 15 (44.1) NS
Age - yrs
Mean 28.9 (24.6-33.2) 23 (19-27) NS
Median 27 19.5 NS
Range 2-80 4-85 NS
Admission diagnosis – no (%)
Medical 14 (41.2%) 14(44.1%) NS
Surgical (non-trauma) 11 (32.4%) 5(14.7%) NS
Trauma 9 (26.5%) 14(41.2%) NS
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Eighteen (26.5%) of 68 patients had new and persistent 
infiltrates reported on Chest X-ray during the 6-day 
period. Only 14 (82.4%) of these satisfied the other 
diagnostic criteria for VAP. The other patients had lung 
collapse, ARDS and a haemothorax. This therefore 
translated to a 20.6% incidence of VAP within six days.
 At intubation, all 68 patients had clear tracheal 
aspirates. Within 48 hours, 29 patients, 17 (50%) in 
the ranitidine group and 12 (35.3%) in the sucralfate 
group had either whitish or purulent secretions. 
By day six, less than half of the ranitidine patients 
still had clear secretions. However, only 14 (56%) of 
those with purulent secretions were diagnosed with 
pneumonia based on their CPIS score. 
 Fifty four (79.4%) of 68 patients were normo-
thermic on admission. The other 14 were febrile, eight 
of whom were randomised to the ranitidine group 
and six to the sucralfate group. Ten (71.4%) of these 
did not acquire any airway infection during the six 
days of follow-up. 23(42.6%) of the normothermic 
patients developed fever during the study period. 
nine (39.1%) of these were found to have pneumonia. 
Two patients who were febrile at admission later had 
a temperature rise of at least 1.5°C above baseline 
and were also diagnosed to have VAP.
Table 2
Clinical and Demographic Characteristics of Patients with Pneumonia
Characteristic Ranitidine (n=8) Sucralfate (n=6) p-value 
Sex – no(%)
Male 3 (37.5) 4 (66.7) NS
Female 5 (62.5) 2 (33.3) NS
Age –yrs
Mean 37.1 41 NS
Median 27 30 NS
Admission diagnosis
Medical 4 (50) 3 (50) NS
Surgical (non-trauma) 1 (12.5) 0 (0) NS
Trauma 3 (37.5) 3 (50) NS
APACHE II score
Mean 11 11 NS
Median 10 10 NS
Mean temperature 38.6 38.8 NS
PaO2/FIO2 ratio 223.8 229.7 NS
WBC count 14.1 13 NS
Mortality 3 (37.5) 2 (33.3) NS
NS= Not significant
Thirty three (24.3%) of 136 gastric aspirates were 
found to be positive after an initial negative culture 
at intubation. These represented 24 (35.3%) of the 68 
study patients, an equal number of whom were on 
ranitidine as were on sucralfate. Eighteen (26.5%) 
patients had gastric colonisation at 48 hours. Gastric 
colonisation at 48 hours occurred more commonly in 
patients on ranitidine than those on sucralfate, but 
this difference was not statistically significant (29.4% 
vs. 23.5%, p=0.3). The total number of those with 
APACHE II score
Mean 10 (4-15) 10 (5-16) NS
Median 9 10 NS
Range 3-24 2-25 NS
NS = Not Significant
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colonised gastric secretions had risen to 24 (35.3%) 
of 68 patients by Day six. 
 Twenty two (16.2%) of 136 paired samples taken 
at 48 hours and on Day six were found to have bacterial 
growth in both tracheal and gastric aspirates. Of these, 
14(63.6%) had the same organism isolated from both 
tracheal and gastric aspirates. These organisms were 
Methicillin-Resistant Staphylococcus aureus (MRSA) in 
9(64.3%), Klebsiella in 4 (28.6%) and Acinetobacter in 1 
(7.1%). Seventy seven point two percent (77.2%) of 
positive cultures were found to have an association 
between the organism isolated from gastric contents 
and that isolated from the airways (p<0.01). 
Tracheal aspirates from 32 (47%) of 68 patients 
were positive for bacterial growth at 48 hours. Of 
these, there was colonisation in 19 (27.9%) patients, 
tracheobronchitis in 19 (27.9%) and pneumonia in 
14(20.6%). By Day six, the number of patients with 
a positive tracheal aspirate number had risen to 
52(76.5%). 25(73.5%)of these were on ranitidine and 
27(79.4%) on sucralfate, a difference that was not 
statistically significant. The organisms isolated at 48 
hours were mainly MRSA and Klebsiella. By Day six, 
the organisms isolated were mainly MRSA, Klebsiella 
and Acinetobacter.
Table 3
Airway infection in study patients
At 48 hrs  
(n=68)







Colonisation 16(23.5) 19(27.9) 9 (26.5) 10 (29.4)
Tracheobronchitis 12(17.6) 19(27.9) 8 (23.5) 11 (32.4)
VAP 4(5.9) 14(20.6) 8 (23.5) 6 (17.6)
Total 32(47.1) 52(76.5) 25(73.5) 27(79.4)
Figures in parentheses represent percentages
Table 4







At 48 hrs  
(n=32)
On day 6  
(n=23)
MRSA 15 (45.5) 22 (41.5) 15(46.9) 8(34.8)
Streptococcus pneumoniae 0 (0) 1 (1.9) 1 (3.1) 0 (0)
Klebsiella 6 (18.2) 15 (26.4) 9 (28.1) 6 (26.1)
Acinetobacter 4 (12.1) 10(18.9) 3 (9.4) 6 (26.1)
Citrobacter 0 (0) 2(3.8) 1 (3.1) 1 (4.3)
Proteus mirabilis 1 (3.0) 2 (3.8) 1 (3.1) 1 (4.3)
Pseudomonas 0 (0) 1 (1.9) 1 (3.1) 0 (0)
E.coli 2 (6.1) 1 (1.9) 0 (0) 1 (4.3)
Enterobacter 5 (15.2) 0 (0) 0 (0) 0 (0)
Positive tracheal aspirates
Early VAP occurred in 4(28.6%) of 14 patients with 
pneumonia. Causative organisms were equally 
distributed between MRSA and Klebsiella. Late-onset 
VAP occurred in 10 (71.4%) of 14 patients, the main 
causative organisms being Acinetobacter in 4 (40%), 
MRSA in 2 (20%), Klebsiella in 2 (20%) and Citrobacter 
in 1 (10%).
The majority of the organisms isolated were resistant 
to first line antibiotics. The highest resistance rates 
were found with penicillin (95.2%) while the lowest 
resistance rates were found with ciprofloxacin (27.4%). 
Resistance rates to cefotaxime, a third-generation 
antibiotic were 50%.
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Table 5
Antibiotic resistance patterns of bacterial isolates
n X-PEN CAF GENT Co-TRIM CEPHAL CEFOT CIPRO
MRSA 36 36(100) 9(25) 18(50) 16(44.4) 14(38.9) 15(41.7) 12(33.3)
Strep pneumo 1 1(100) 1(100) 1(100) 1(100) 0(0) 0(0) 0(0)
Klebsiella 19 18(94.7) 12(63.2) 7(36.8) 9(47.4) 12(63.2) 5(26.3) 3(15.8)
Acinetobacter 14 11(78.6) 14(100) 10(71.4) 8(57.1) 14(100) 12(85.7) 4(28.6)
Enterobacter 5 5(100) 3(60) 4(80) 4(80) 5(100) 4(80) 0(0)
E. Coli 3 3(100) 2(66.7) 2(66.7) 2(66.7) 3(100) 2(66.7) 1(33.3)
Proteus 3 3(100) 3(100) 2(66.7) 3(100) 3(100) 2(66.7) 2(66.7)
Citrobacter 2 2(100) 2(100) 2(100) 2(100) 2(100) 1(50) 0(0)
Pseudomonas 1 1(100) 1(100) 0(0) 1(100) 1(100) 1(100) 1(100)
TOTAL 84 80(95.2) 47(56.0) 46(54.8) 46(54.8) 54(64.3) 42(50) 23(27.4)
Key: X-PEN Crystalline penicillin; CAF chloramphenicol; GENT gentamicin; CEPHAL cephalothin; CEFOT 
cefotaxime; CIPRO ciprofloxacin, CO-TRIM Co-trimoxazole
n= total number of isolates
Figures in parentheses represent percentages
Twenty two (32.4%) of the 68 patients in the study 
died within six  days in ICU. The overall mortality 
in the KNH ICU during this period was 33.6%. There 
was a 17.7% higher mortality rate in patients on 
sucralfate versus those on ranitidine (41.2% vs. 23.5%, 
p=0.5). This difference however was not statistically 
significant. There was no statistically significant 
difference between the two groups in terms of age, sex, 
APACHE II score, degree of gastric colonisation or any 
airway infection in those who died. Fourteen (63.6%)
of the 22 patients who died had acquired airway 
colonisation, tracheobronchitis or VAP while in ICU. 
Table 6
Characteristics of the patients who died
Characteristic Patients who died  




Mean age, range (yrs) 32.5 36.8 (17.8-55.8) 30.3 (4.4-56.2)
Males – no. (%) 11(50) 5 (62.5) 6 (42.9)
Mean APACHE II score 12 12 (6-18) 12 (6-18)
Medical cases – no. (%) 10(45.5) 2 (25) 8 (57.1)
Trauma cases – no. (%) 7(31.8) 3 (37.5) 4 (28.6)
Gastric colonisation – no. (%) 9(40.9) 4 (50) 5 (35.7)
Any airway infection –no. (%) 14(63.6) 5 (62.5) 9 (64.3)
Mortality by group
DISCUSSION
This study showed that the rate of bacterial infection 
in intubated patients at the KNH ICU is high, occurs 
early and rapidly progresses to more severe infection.
 Within 48 hours of admission, nearly half 
the study patients had airway colonisation, 
tracheobronchitis or pneumonia. By Day 6, 76.5% of 
patients had positive bacterial cultures on tracheal 
aspirate. 
 The incidence of early-onset VAP was low (5.9%), 
which compared well with other studies. Although 
three times as many patients on ranitidine had 
acquired VAP as compared to those on sucralfate, 
this was not statistically significant. However, the 
presence of MRSA and gram-negative organisms such 
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as Klebsiella at 48 hours was unusual and would imply 
that the source of these organisms is contaminated 
airway management equipment within the ICU. 
 There was a causal relationship between bacteria 
isolated from gastric secretions and those found 
in patients’ airways. Selective decontamination of 
the digestive tract (SDD) has for this reason been 
advocated in some centres as being invaluable in 
preventing gastric colonisation and subsequent 
pneumonia and/or sepsis in intubated patients. 
This has not been universally accepted however, as 
it may lead to the development of antibiotic-resistant 
organisms in critical care units (13).
 Sixty eight point two percent (68.2%) of patients 
who died had airway colonisation, tracheobronchitis 
or pneumonia. Although the mortality in the sucralfate 
group was almost 9% higher than that in the ranitidine 
group, this was not statistically significant. Of note 
however is the fact that 22.7% of the patients who 
died had been diagnosed with VAP. Mortality rates 
in patients with pneumonia in the two groups were 
approximately equal (33.3% of those on sucralfate 
and 37.5% of those on ranitidine). 
 The organisms isolated from these patients 
were multi-drug resistant. Very few were sensitive 
to first-line antibiotics and as such the use of these 
antibiotics in critically ill patients presenting to 
this unit needs to be reviewed. A previous study 
conducted in the KNH ICU had identified the third 
generation antibiotic ceftazidime as proving the best 
broad-spectrum cover. The lack of sensi-discs for this 
antimicrobial however meant that sensitivity patterns 
to ceftazidime were not tested. There was a worryingly 
high rate of Methicillin-Resistant Staphylococcus aureus 
(MRSA), a virulent organism with a high morbidity 
and mortality in infected patients, which requires 
stringent infection control measures to prevent and 
control. 
 Colonisation, tracheobronchitis and pneumonia 
rates were similar between patients on sucralfate and 
those on ranitidine. In addition, the rates of gastric 
colonisation were the same in both treatment groups 
(23.5%). This study therefore failed to demonstrate 
any protective effect of using sucralfate as stress ulcer 
prophylaxis. The common use of enteral feeds in the 
KNH ICU may have been a potential confounder, as 
it would result in an alteration in gastric pH levels. 
This was not adjusted for in the analysis. 
 Despite the lack of a protective effect on gastric 
colonisation or VAP in critically ill African patients, 
stress ulcer prophylaxis with sucralfate may still be 
a viable alternative for stress ulcer prophylaxis in 
resource-limited countries, due to its lower cost.
LIMITATIONS OF THE STUDY
Fungal and viral pneumonias were not accounted for, 
as the cultures for these would have been too costly 
to perform. The use of tracheal aspirate samples 
and the CPIS scoring system are of low specificity 
in diagnosing VAP. Bronchoscopically directed 
techniques may have increased the proportion 
of positive cultures, but these were however not 
available at the Kenyatta National Hospital ICU. 
Previous unreported antibiotic use may also have 
interfered with culture results.
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